Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US-2017362573-A1 · Dec 21, 2017 · US
US11326149B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11326149-B2 |
| Application number | US-201816051004-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 31, 2018 |
| Priority date | Feb 1, 2016 |
| Publication date | May 10, 2022 |
| Grant date | May 10, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
Opening claim text (preview).
The invention claimed is: 1. A method of culturing cells, comprising: a) providing a microfluidic device comprising a membrane, said membrane comprising a top surface and a bottom surface; b) selecting single intestinal organoid cells that express E-cadherin to produce selected single intestinal organoid cells; c) seeding said selected single intestinal organoid cells on said top surface so as to create seeded cells; d) exposing said seeded cells to a flow of culture media for a period of time; and e) culturing said seeded cells under conditions such that organoid cells mature and/or differentiate into intestinal cells comprising absorptive cells, goblet cells, enteroendocrine cells, and Paneth cells. 2. The method of claim 1 , wherein said micro fluidic device comprises a first microfluidic channel in fluidic communication with said top surface of said membrane and a second microfluidic channel in fluidic communication with said bottom surface of said membrane, said first and second microfluidic channels each comprising a surface that is parallel to said membrane, and each comprising side walls. 3. The method of claim 1 , wherein said organoid cells are from organoids derived from human induced pluripotent stem cells. 4. The method of claim 1 , wherein said selected cells are frozen, stored and subsequently thawed prior to step c). 5. The method of claim 3 , wherein said induced pluripotent stem cells are from a human patient diagnosed with a gastrointestinal disorder. 6. The method of claim 5 , wherein said induced pluripotent stern cells are from a patient diagnosed with Inflammatory bowel disease (IBD). 7. The method of claim 5 , wherein said induced pluripotent stem cells are from a patient diagnosed with colitis. 8. A method of culturing cells, comprising: a) providing i) stem-cell derived organoid cells and ii) a microfluidic device comprising a membrane, said membrane comprising a top surface and a bottom surface; b) selecting single stem-cell derived organoid cells that express E-cadherin to produce selected single stem-cell derived organoid cells; c) freezing and storing said selected cells to produce stored cells; d) thawing and seeding said stored cells on said top surface of the membrane of said microfluidic device so as to create seeded cells; e) exposing said seeded cells to a flow of culture media for a period of time; and f) culturing said seeded cells under conditions such that said selected cells mature and/or differentiate into intestinal cells comprising absorptive cells, goblet cells, enteroendocrine cells, and Paneth cells. 9. The method of claim 8 , wherein said intestinal cells intestinal cells are selected from the group consisting of foregut intestinal epithelial cells, midgut intestinal epithelial cells and hindgut intestinal epithelial cells. 10. The method of claim 8 , wherein said microfluidic device comprises a first microfluidic channel in fluidic communication with said top surface of said membrane and a second microfluidic channel in fluidic communication with said bottom surface of said membrane, said first and second microfluidic channels each comprising a surface that is parallel to said membrane, and each comprising side walls. 11. The method of claim 8 , wherein said storing said selected cells in step c) is performed for at least one month. 12. The method of claim 8 , wherein said selected cells comprise foregut progenitors, midgut progenitors and/or hindgut progenitors. 13. The method of claim 8 , wherein said organoids are derived from human induced pluripotent stem cells. 14. The method of claim 8 , wherein said organoids are derived from induced pluripotent stem cells from a human patient diagnosed with a gastrointestinal disorder. 15. The method of claim 14 , wherein said induced pluripotent stem cells are from a patient diagnosed with Inflammatory bowel disease (IBD). 16. The method of claim 14 , wherein said induced pluripotent stem cells are from a patient diagnosed with colitis. 17. A method of culturing cells, comprising: a) providing a microfluidic device comprising a membrane, said membrane comprising a first surface and a second surface; b) selecting single intestinal organoid cells that express E-cadherin to produce selected single intestinal organoid cells by cell sorting; c) seeding said selected single intestinal organoid cells on said first surface so as to create seeded cells; d) exposing said seeded cells to a flow of culture media for a period of time; and e) culturing said seeded cells under conditions such that organoid cells mature and/or differentiate into intestinal cells comprising one or more of absorptive cells, goblet cells, enteroendocrine cells and Paneth cells. 18. The method of claim 17 , wherein said microfluidic device comprises a first microfluidic channel in fluidic communication with said first surface of said membrane and a second microfluidic channel in fluidic communication with said second surface of said membrane, said first and second microfluidic channels each comprising a surface that is parallel to said membrane, and each comprising side walls. 19. A method of culturing cells, comprising: a) providing i) a microfluidic device comprising a membrane, said membrane comprising a top surface and a bottom surface, and ii) intestinal enteroids; b) dissociating said intestinal enteroids to produce intestinal enteroid single cells; c) selecting said intestinal enteroid single cells for E-cadherin expression to produce selected intestinal enteroid single cells; d) seeding said selected intestinal enteroid single cells on said top surface so as to create seeded cells; e) exposing said seeded cells to a flow of culture media for a period of time; and f) culturing said seeded cells under conditions such that organoid cells mature and/or differentiate into intestinal cells comprising absorptive cells, goblet cells, enteroendocrine cells, and Paneth cells. 20. The method of claim 19 , wherein said microfluidic device comprises a first microfluidic channel in fluidic communication with said first surface of said membrane and a second microfluidic channel in fluidic communication with said second surface of said membrane, said first and second microfluidic channels each comprising a surface that is parallel to said membrane, and each comprising side walls.
Activin; Inhibin; Mullerian inhibiting substance · CPC title
Artificially induced pluripotent stem cells, e.g. iPS · CPC title
Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor · CPC title
Supports or coatings for cell culture characterised by topography · CPC title
from artificially induced pluripotent stem cells · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.